Anteris Technologies has revealed that a successful procedure of its DurAVR transcatheter aortic valve (THV) took place in a Canadian study as the company continues to build up positive clinical evidence for the device. Implanted in patients as part of…
QiLu’s ALK inhibitor meets Phase III primary endpoint in NSCLC
China-based QiLu Pharmaceutical has announced positive data from a Phase III trial investigating iruplinalkib in patients with non-small cell lung cancer (NSCLC). The data analysis showed that the primary endpoint of progression-free survival (PFS) met the pre-defined criteria. Additionally, PFS…
Verily and OneOncology establish partnership for clinical trials
Alphabet precision health technology company Verily and OneOncology have announced a strategic collaboration for clinical trials. Under the partnership, community OneOncology Research Network sites will get access to new tools for expediting trials and improving their cancer care delivery. Verily’s…
Ocugen plans two Phase I/II trials in macular disease
Phase I/II trials for Ocugen’s gene therapies, OCU410 and OCU410ST, are planned for initiation by the end of 2023 in geographic atrophy and Stargardt disease. The plans follow the US Food and Drug Administration’s (FDA) approval of the Investigational New…
